STAT+: Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy
In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound pharmacy of selling versions of its Wegovy and Ozempic medicines, which are widely prescribed for…
In a setback for Novo Nordisk, a U.S. judge dismissed its lawsuit accusing a compound pharmacy of selling versions of its Wegovy and Ozempic medicines, which are widely prescribed for weight loss and have become franchise products for the drug company.
The decision, which was conveyed in a one-page filing in the court docket, comes after Novo Nordisk filed lawsuits last July against Brooksville Pharmaceuticals and three other compound pharmacies for allegedly violating laws in different states. The drug maker argued the compounders were selling versions of its medicines that were never approved by the U.S. Food and Drug Administration.
The compound pharmacy declined to comment, as did its attorney, Matthew Modafferi. However, he explained that U.S. District Court Judge William Jung left the door open for Novo Nordisk to file an amended lawsuit. This suggests the case may continue if drug maker takes such a step. A Novo Nordisk spokeswoman declined to comment until Jung files his order in the docket.
What's Your Reaction?
